Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $34.20 Consensus PT from Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $36.00.

Several research analysts recently issued reports on the stock. Piper Sandler raised their target price on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday. Wedbush upped their target price on Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Finally, Wall Street Zen lowered Tyra Biosciences from a “hold” rating to a “sell” rating in a report on Saturday.

Insider Activity at Tyra Biosciences

In other news, Director Robert J. More sold 10,000 shares of Tyra Biosciences stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director directly owned 3,823,425 shares of the company’s stock, valued at $95,585,625. The trade was a 0.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.20% of the stock is owned by insiders.

Institutional Trading of Tyra Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. HighVista Strategies LLC raised its position in shares of Tyra Biosciences by 4.3% in the second quarter. HighVista Strategies LLC now owns 24,962 shares of the company’s stock worth $239,000 after acquiring an additional 1,021 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after purchasing an additional 1,841 shares in the last quarter. Rhumbline Advisers raised its holdings in Tyra Biosciences by 7.2% in the 1st quarter. Rhumbline Advisers now owns 28,081 shares of the company’s stock worth $261,000 after purchasing an additional 1,879 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in Tyra Biosciences by 27.7% during the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock worth $178,000 after purchasing an additional 2,766 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Stock Down 1.7%

Shares of NASDAQ TYRA opened at $30.37 on Friday. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $31.56. The business’s 50 day moving average price is $24.66 and its 200 day moving average price is $16.77. The firm has a market cap of $1.62 billion, a P/E ratio of -16.24 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.50). As a group, research analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.